RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback